Study on the molecular mechanisms of rituximab action and the enhancement of its actions

为了研究利妥昔单抗疗效异质性的分子机制，通过ADCC和CDC测定分析了从弥漫性大B细胞淋巴瘤（DLBCL）患者建立的细胞系的利妥昔单抗敏感性。对DLBCL患者肿瘤标本进行CD79B、CARD 11和EZH2基因突变检测，并分析其与DLBCL患者病情的相关性。DLBCL细胞系对利妥昔单抗的体外敏感性显示其DLBCL亚型没有明确的模式。CD79B、CARD11和EZH2在几名患者中显示出体细胞突变，并且具有突变的CARD11基因的患者显示出显著差的表达。

To investigate the molecular mechanisms of heterogeneity in rituximab efficacies, rituximab-sensitivities of cell lines established from patients with diffuse large B-cell lymphoma (DLBCL) were analyzed by ADCC and CDC assays. Tumor samples from patients with DLBCL were evaluated for their mutations on CD79B, CARD11 and EZH2, and their correlations with the prognoses of the patients were analyzed. In vitro sensitivity of DLBCL cell lines to rituximab showed no clear patterns with respect to their DLBCL subtypes. CD79B, CARD11 and EZH2 showed somatic mutations in several patients, and patients with mutated CARD11 genes showed significant poor prognoses.